There are two previously unreported problems with the stem cell lines approved by the Bush administration, the Washington Post reports today. One study finds that all approved lines share a previously unrecognized trait that fosters rejection by the immune systems, “diminishing their potential as medical treatments.” And another study has concluded that at least one-fourth of the approved lines (there are 22 of them) are so difficult to keep alive that they have little potential, even as research tools.
Such news may be too late to affect the presidential election–and no doubt anyone who’s going to vote on the single issue of stem cells has already made up his or her mind one way or the other–but it might add yet more wood on the fire of California’s Proposition 71. In a recent poll, 53% of respondents favored Prop. 71’s passage and only 34% opposed.
Embracing CX in the metaverse
More than just meeting customers where they are, the metaverse offers opportunities to transform customer experience.
Identity protection is key to metaverse innovation
As immersive experiences in the metaverse become more sophisticated, so does the threat landscape.
The modern enterprise imaging and data value chain
For both patients and providers, intelligent, interoperable, and open workflow solutions will make all the difference.
Scientists have created synthetic mouse embryos with developed brains
The stem-cell-derived embryos could shed new light on the earliest stages of human pregnancy.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.